Blood drawn by people themselves from a fingerprick at home, then posted to a lab, produced Alzheimer's biomarker readings that closely matched those from conventional venous samples taken in a clinic, according to a study published in Nature Communications. The researchers measured plasma phosphorylated tau 217 (p-tau217) and glial fibrillary acidic protein (GFAP), two proteins that have emerged as reliable blood-based signals of Alzheimer's-related pathology, in capillary samples collected by participants without a phlebotomist present.
The levels of those markers also tracked with how well participants performed on cognitive and functional measures across the Alzheimer's continuum. When the fingerprick results were paired with computerized cognitive tests that can be completed online, the combination looked capable of supporting remote triage - flagging people whose biology and test performance together suggest elevated risk of Alzheimer's-related impairment.
The practical significance lies in reach. Many people with early cognitive changes never make it to a memory clinic, and the requirement for a venous draw at a specialist site keeps biomarker testing out of reach for those who are rural, less mobile, or simply not yet referred. A test that can be done at a kitchen table and dropped in the post removes several of those barriers at once. Participants also found the approach highly acceptable, which matters for any screening tool that depends on people actually completing it.
The authors are explicit that this is risk stratification, not diagnosis. A raised p-tau217 or GFAP result from a home kit would be a reason for further clinical assessment, not an answer in itself. What the work establishes is that the sample quality holds up outside the clinic, which is the technical hurdle that has stood between promising blood biomarkers and population-scale use.